Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Ally Bridge Group
AddedFeb 13, 2024
UpdatedJun 28, 2026
Ally Bridge Group

Ally Bridge Group

Operating

Ally Bridge Group: A global leader in life science-focused investments.

Location
New York City, NY, US
Founded
2013
Firm
Compare
Portfolio
Employees
Website

Investments

RefleXion Medical
RefleXion Medical

Total Raised

$675.1M

Rounds

11

Series Unknown$105MNovember 2023
Series Unknown$80MMarch 2022
Series D$40MMarch 2021
Vida Health
Vida Health

Total Raised

$216.5M

Rounds

6

Series Unknown$28.5MNovember 2023
Series D$110MMay 2021
Lightforce Orthodontics
Lightforce Orthodontics

Total Raised

$150.6M

Rounds

6

Series D$80MAugust 2023
Relievant Medsystems
Relievant Medsystems
Public

Total Raised

$273.6M

Rounds

9

Series G$50MMarch 2023
Ceribell
Ceribell

Total Raised

$220.5M

Rounds

5

Series C$50MSeptember 2022
Syapse
Syapse
Public

Total Raised

$222.6M

Rounds

9

Series Unknown$35MJuly 2022
Series Unknown$68MFebruary 2021
Aerin Medical
Aerin Medical

Total Raised

$190.5M

Rounds

8

Private Equity$60MJune 2022
Endeavor Biomedicines
Endeavor Biomedicines

Total Raised

$163M

Rounds

2

Series B$101MFebruary 2022
Transcarent
Transcarent

Total Raised

$298M

Rounds

3

Series C$200MJanuary 2022
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series B$215MNovember 2021
Shoreline Biosciences
Shoreline Biosciences

Total Raised

$186M

Rounds

3

Series B$140MNovember 2021
Elligo Health Research
Elligo Health Research

Total Raised

$196M

Rounds

6

Series E$135MSeptember 2021
Sonoma Biotherapeutics
Sonoma Biotherapeutics

Total Raised

$365M

Rounds

4

Series B$265MAugust 2021
Imperative Care
Imperative Care

Total Raised

$409M

Rounds

5

Series D$260MJuly 2021
Strateos
Strateos

Total Raised

$105.8M

Rounds

12

Series B$56.1MJune 2021
NiKang Therapeutics
NiKang Therapeutics

Total Raised

$260M

Rounds

3

Series C$200MMay 2021
Ultivue
Ultivue

Total Raised

$107.3M

Rounds

5

Series D$50MApril 2021
Syros Pharmaceuticals
Syros Pharmaceuticals
Public

Total Raised

$620.5M

Rounds

12

Post Ipo Equity$90.5MDecember 2020
Cogent Biosciences
Cogent Biosciences
Public

Total Raised

$692.7M

Rounds

10

Post Ipo Equity$104.4MJuly 2020
Goldfinch Bio
Goldfinch Bio
Public

Total Raised

$210M

Rounds

3

Series B$100MJune 2020
Rapid Micro Biosystems
Rapid Micro Biosystems
Public

Total Raised

$377.4M

Rounds

12

Private Equity$120MMay 2020